Cargando…
Immunogenicity assay of the Leishmune(®) vaccine against canine visceral leishmaniasis in Brazil
Leishmune(®) is the industrialized version of the FML-saponin vaccine which has been shown to develop 92–95% protection in vaccinated dogs and 76–80% vaccine efficacy against field canine visceral leishmaniasis (CVL) in Brazil. Leishmune(®) has been proven to be safe and tolerable and a transmission...
Autores principales: | Borja-Cabrera, G.P., Santos, F.N., Bauer, F.S., Parra, L.E., Menz, I., Morgado, A.A., Soares, I.S., Batista, L.M.M., Palatnik-de-Sousa, C.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173152/ https://www.ncbi.nlm.nih.gov/pubmed/18675868 http://dx.doi.org/10.1016/j.vaccine.2008.07.029 |
Ejemplares similares
-
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune(®) vaccine
por: Santos, F.N., et al.
Publicado: (2007) -
Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis
por: Borja-Cabrera, GP, et al.
Publicado: (2009) -
Phase I and II Clinical Trial Comparing the LBSap, Leishmune(®), and Leish-Tec(®) Vaccines against Canine Visceral Leishmaniasis
por: Aguiar-Soares, Rodrigo Dian de Oliveira, et al.
Publicado: (2020) -
Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine
por: Borja-Cabrera, Gulnara Patricia, et al.
Publicado: (2004) -
Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis
por: de Mendonça, Ludmila Zanandreis, et al.
Publicado: (2016)